Post-approval studies (Phase 4)UnknownNCT01170338
What this trial is testing
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Who this might be right for
SmokingAcute Coronary Syndrome
Newark Beth Israel Medical Center 100